Literature DB >> 11226817

Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers.

R Gref1, P Quellec, A Sanchez, P Calvo, E Dellacherie, M J Alonso.   

Abstract

Cyclosporin A (CyA) loaded poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) micro- and nanoparticles have been developed using an emulsion-solvent evaporation method. Physico-chemical properties, peptide loading content and in vitro release profiles of these novel CyA carriers were compared with those corresponding to conventional PLA micro- and nanoparticles. Results obtained confirm the previously described disposition of PEG chains on the surface of the PLA-PEG formulations. In addition, they revealed the presence of CyA molecules on the surface of both PLA and PLA-PEG systems. Further determination of the surface chemical composition by electron spectroscopy for chemical analysis (ESCA) allowed us to quantify the amount of CyA in the nanospheres' top layers, this amount being higher for nanoparticles than for microparticles, and higher for the PLA systems than for those based on PLA-PEG. In vitro release experiments revealed that PLA-PEG particles provided a more adequate control of CyA release than conventional PLA micro- and nanoparticles. Physico-chemical characterization of the systems during the release studies showed that the developed PLA and PLA-PEG micro- and nanoparticles were not degraded, which suggest a diffusion-mediated release mechanism. Furthermore, we have hypothesized that the hydrophilic outer shell of PEG provides a stationary layer for the diffusion of CyA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226817     DOI: 10.1016/s0939-6411(00)00143-0

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  19 in total

1.  Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.

Authors:  D D Ankola; A Battisti; R Solaro; M N V Ravi Kumar
Journal:  J R Soc Interface       Date:  2010-05-26       Impact factor: 4.118

Review 2.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

Review 3.  Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.

Authors:  A N Ilinskaya; M A Dobrovolskaia
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

4.  Polymeric micelles based on amphiphilic scorpion-like macromolecules: novel carriers for water-insoluble drugs.

Authors:  Jelena Djordjevic; Maryan Barch; Kathryn E Uhrich
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

5.  Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells.

Authors:  Mira F Francis; Mariana Cristea; Yali Yang; Françoise M Winnik
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

6.  Cryo-electron tomography investigation of serum albumin-camouflaged tobacco mosaic virus nanoparticles.

Authors:  Neetu M Gulati; Andrzej S Pitek; Nicole F Steinmetz; Phoebe L Stewart
Journal:  Nanoscale       Date:  2017-03-09       Impact factor: 7.790

7.  Biocompatible Nanocomplexes for Molecular Targeted MRI Contrast Agent.

Authors:  Zhijin Chen; Dexin Yu; Shaojie Wang; Na Zhang; Chunhong Ma; Zaijun Lu
Journal:  Nanoscale Res Lett       Date:  2009-03-18       Impact factor: 4.703

8.  Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties.

Authors:  Thibault Ameller; Véronique Marsaud; Philippe Legrand; Ruxandra Gref; Gillian Barratt; Jack-Michel Renoir
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

9.  Emulsification/internal gelation as a method for preparation of diclofenac sodium-sodium alginate microparticles.

Authors:  Mahmoud M Ahmed; Saleh Abd El-Rasoul; Sayed H Auda; Mohamed A Ibrahim
Journal:  Saudi Pharm J       Date:  2011-09-08       Impact factor: 4.330

10.  Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy.

Authors:  João G Marques; Vítor M Gaspar; David Markl; Elisabete C Costa; Eugénia Gallardo; Ilídio J Correia
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.